Michael Smylie
Contact
Faculty of Medicine & Dentistry - Oncology Dept
- msmylie@ualberta.ca
- Phone
- (780) 432-8757
- Address
-
Cross Cancer Institute
11560 University AvenueEdmonton ABT6G 1Z2
Overview
Area of Study / Keywords
About
Dr. Michael Smylie is currently appointed as Professor in the Department of Oncology in the Faculty of Medicine & Dentistry.Research
Melanoma and Lung Cancers
- Site Leader – Clinical Trials Committee – Cross Cancer Institute NCIC Melanoma Group Leader and very active in designing and participating in malignant melanoma.
- Targeted therapy and new drug development in metastatic melanoma.
- He has chaired several National Melanoma Meetings and organized the past three National Melanoma Conferences in Canada.
- Chair – Mary Johnston Professorship in Melanoma Research – 2006-2007. This is a $1,000,000 donation from the Mary Johnston family and the Alberta Government through their endowment fund has guaranteed to match this contribution dollar for dollar. In recognition of this patient and her family, Cross Cancer Institute has created the endowed Mary Johnston Professorship in melanoma research. In October of 2007, Alan Underhill, Department of Medical Genetics of the University of Alberta took over the Chair Position of this Professorship. Underhill and Dr. Smylie are keen in objectives in basic research to identify targets in melanoma. This is the first research in this field in Canada.
Featured Publications
Hung W., Cusnir I., Habib S., Smylie M., Solez K., Yacyshyn E.
Rheumatology (United Kingdom). 2021 June; 60 (6):E190-E191 10.1093/rheumatology/keaa818
ASCO 2021. 2021 May; 10.1200/JCO.2021.39.15_suppl.9506
ASCO 2021. 2021 May; 10.1200/JCO.2021.39.15_suppl.9516
Youn S., Reif R., Chu M.P., Smylie M., Walker J., Eurich D.T., Ghosh S., Sawyer M.B.
Clinical Nutrition ESPEN. 2021 April; 42 10.1016/j.clnesp.2021.01.009
Hodi F.S., Chapman P.B., Sznol M., Lao C.D., Gonzalez R., Smylie M., Daniels G.A., Thompson J.A., Kudchadkar R., Sharfman W., Atkins M., Spigel D.R., Pavlick A., Monzon J., Kim K.B., Ernst S., Khushalani N.I., Van Dijck W., Lobo M., Hogg D.
Melanoma Research. 2021 February; 10.1097/CMR.0000000000000708
AlZahrani F., Kuzel P., Metelitsa A., Smylie M., Dover D., Fiorillo L.
Journal of Cutaneous Medicine and Surgery. 2020 October; 25 (2):133-141 10.1177/1203475420963658
Hogg D., Monzon J.G., Savage J., Skinn B., Ernst S., Song X., McWhirter E., Romeyer F., Smylie M.
Current Oncology. 2020 August; 27 (4):204-214 10.3747/co.27.5985
Ascierto P.A., Del Vecchio M., Mackiewicz A., Robert C., Chiarion-Sileni V., Arance A., Lebbé C., Svane I.M., Mcneil C., Rutkowski P., Loquai C., Mortier L., Hamid O., Bastholt L., Dreno B., Schadendorf D., Garbe C., Nyakas M., Grob J.J., Thomas L., Liszkay G., Smylie M., Hoeller C., Ferraresi V., Grange F., Gutzmer R., Pikiel J., Hosein F., Simsek B., Maio M.
Journal for ImmunoTherapy of Cancer. 2020 June; 8 (1) 10.1136/jitc-2019-000391
Chu M.P., Li Y., Ghosh S., Sass S., Smylie M., Walker J., Sawyer M.B.
Journal of Cachexia, Sarcopenia and Muscle. 2020 June; 11 (3):748-755 10.1002/jcsm.12538
Journal of Clinical Oncology. 2020 May; 10.1200/JCO.2020.38.15_suppl.10019
Suo A., Chan Y., Beaulieu C., Kong S., Cheung W.Y., Monzon J.G., Smylie M., Walker J., Morris D., Cheng T.
Oncologist. 2020 May; 25 (5):438-446 10.1634/theoncologist.2019-0674
Smylie M.G.
Current Oncology. 2020 January; 27 (S2):51-58 10.3747/co.27.5135
Ganesan A., Ahmed M., Okoye I., Arutyunova E., Babu D., Turnbull W.L., Kundu J.K., Shields J., Agopsowicz K.C., Xu L., Tabana Y., Srivastava N., Zhang G., Moon T.C., Belovodskiy A., Hena M., Kandadai A.S., Hosseini S.N., Hitt M., Walker J., Smylie M., West F.G., Siraki A.G., Lemieux M.J., Elahi S., Nieman J.A., Tyrrell D.L., Houghton M., Barakat K.
Scientific Reports. 2019 December; 9 (1) 10.1038/s41598-019-48826-6
Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D., Cowey C.L., Schadendorf D., Wagstaff J., Dummer R., Ferrucci P.F., Smylie M., Hogg D., Hill A., Márquez-Rodas I., Haanen J., Guidoboni M., Maio M., Schöffski P., Carlino M.S., Lebbé C., McArthur G., Ascierto P.A., Daniels G.A., Long G.V., Bastholt L., Rizzo J.I., Balogh A., Moshyk A., Hodi F.S., Wolchok J.D.
New England Journal of Medicine. 2019 October; 381 (16):1535-1546 10.1056/NEJMoa1910836
Annals of Oncology. 2019 October; 10.1093/annonc/mdz255
LBA68_PR - 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
Annals of Oncology. 2019 September;